Open AccessComparison of Treatments for Nonmetastatic Castration-Resistant Prostate Cancer: Matching-Adjusted Indirect Comparison and Network Meta-Analysis
Author(s) -
Lin Wang,
Sean A. Fletcher,
Hwanhee Hong,
Lori Rosman,
Anthony De Felice,
Otis W. Brawley,
G. Caleb Alexander
Publication year - 2021
Publication title -
journal of the national cancer institute
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.797
H-Index - 356
eISSN - 1460-2105
pISSN - 0027-8874
DOI - 10.1093/jnci/djab071
Subject(s) - enzalutamide , medicine , hazard ratio , prostate cancer , placebo , odds ratio , adverse effect , confidence interval , randomized controlled trial , abiraterone acetate , oncology , cancer , androgen deprivation therapy , androgen receptor , alternative medicine , pathology
For nonmetastatic castration-resistant prostate cancer (nmCRPC), 3 drugs under patent protection-apalutamide, enzalutamide, and darolutamide-were approved based on randomized, placebo-controlled trials; 1 drug with generic availability, abiraterone acetate, showed efficacy in a single-arm trial and is commonly prescribed. Lacking head-to-head trials, the optimal treatment for nmCRPC is unknown, despite widely varied treatment costs. We compared the efficacy and safety of nmCRPC treatments.